China has issued a notification of patent grant to bioAffinity for its novel method of using siRNAs to selectively kill ...

DelveInsight's analysis shows that the UK reported the highest number of DED cases in individuals aged 50 and older, with ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set a goal of targeting small interfering RNA to any tissue by 2030.

Detailed price information for Generation Bio Co. (GBIO-Q) from The Globe and Mail including charting and trades.

State Key Laboratory of Organic−Inorganic Composites, Beijing University of Chemical Technology, Beijing 100029, China ...

Mark Nestor's team from the Center for Clinical and Cosmetic Research in Miami Florida has jointly published a major breakthrough for its novel siRNA therapeutics revealing a novel mechanism of action ...

Mark Nestor’s team from the Center for Clinical and Cosmetic Research in Miami Florida has jointly published a major breakthrough for its novel siRNA therapeutics revealing a novel mechanism of ...

As an essential component of the RNA interference (RNAi) pathway, siRNA works by degrading target messenger RNA (mRNA) molecules, thereby preventing them from being translated into proteins. This ...

Recent developments, such as the approval of new siRNA-based drugs and advancements in delivery mechanisms are signaling a promising era for gene-targeted therapies. The siRNA technology sector is ...

Mechanism of siRNA action. The method by which siRNA causes the silencing of genes is as follows: Double-stranded RNA is cleaved by the Dicer enzyme. This forms siRNA.